美国慢性症状性功能性肠病的流行病学负担与治疗:一项全国性分析
基于美国全国门诊医疗调查2007—2015年数据,估算慢性症状性功能性肠病门诊就诊率与费用,并评估药物与非药物治疗模式。
要点
- 药物治疗占49.7%,非药物干预占19.8%,两者差异有统计学意义(P < .001)。
- 仅不足五分之一的门诊就诊包含非药物治疗策略。
核心结论
- 慢性症状性功能性肠病的管理与相当大的医疗资源使用和费用相关。
- 由于不足五分之一的门诊就诊包含非药物治疗策略,可能存在改善功能性肠病综合管理的机会。
研究设计与样本
- 研究使用美国全国门诊医疗调查(National Ambulatory Medical Care Survey)数据,估算症状性肠易激综合征、慢性功能性腹痛、便秘或腹泻的门诊就诊年率及相关费用。
- 计算与药物和非药物(压力/心理健康、运动、饮食咨询)干预相关的加权就诊比例,并用多变量多项逻辑回归评估治疗策略的预测因素。
主要发现
- 药物治疗在49.7%(95% CI,44.7—54.8)的就诊中被处方,而非药物干预为19.8%(95% CI,16.0—24.2),差异有统计学意义(P < .001)。
- 联合治疗策略更可能由基层医生实施,也更可能用于患有抑郁或肥胖的患者。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Functional bowel disorders (FBDs) are the most common gastrointestinal problems managed by physicians. We aimed to assess the burden of chronic symptomatic FBDs on ambulatory care delivery in the United States and evaluate patterns of treatment. METHODS: Data from the National Ambulatory Medical Care Survey were used to estimate annual rates and associated costs of ambulatory visits for symptomatic irritable bowel syndrome, chronic functional abdominal pain, constipation, or diarrhea. The weighted proportion of visits associated with pharmacologic and nonpharmacologic (stress/mental health, exercise, diet counseling) interventions were calculated, and predictors of treatment strategy were evaluated in multivariable multinomial logistic regression. RESULTS: From 2007-2015, approximately 36.9 million (95% CI, 31.4-42.4) weighted visits in patients of non-federally employed physicians for chronic symptomatic FBDs were sampled. There was an annual weighted average of 2.7 million (95% CI, 2.3-3.2) visits for symptomatic irritable bowel syndrome/chronic abdominal pain, 1.0 million (95% CI, 0.8-1.2) visits for chronic constipation, and 0.7 million (95% CI, 0.5-0.8) visits for chronic diarrhea. Pharmacologic therapies were prescribed in 49.7% (95% CI, 44.7-54.8) of visits compared to nonpharmacologic interventions in 19.8% (95% CI, 16.0-24.2) of visits (P < .001). Combination treatment strategies were more likely to be implemented by primary care physicians and in patients with depression or obesity. The direct annual cost of ambulatory clinic visits alone for chronic symptomatic FBDs is approximately US$358 million (95% CI, 233-482 million). CONCLUSIONS: The management of chronic symptomatic FBDs is associated with considerable health care resource use and cost. There may be an opportunity to improve comprehensive FBD management because fewer than 1 in 5 ambulatory visits include nonpharmacologic treatment strategies.
引用
- Ma C, Congly SE, Novak KL, et al. Epidemiologic Burden and Treatment of Chronic Symptomatic Functional Bowel Disorders in the United States: A Nationwide Analysis. Gastroenterology. 2020. PMID: 33010247. doi:10.1053/j.gastro.2020.09.041
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。